Lilly Mark

2.2k citations

19 papers · 1.4k indexed · h-index 15

Impact in

Sensory Systems top 2%
- Ion Channels and Receptors
Pharmacology top 2%
- Cannabis and Cannabinoid Research

Papers in ⓘ

Molecular Biology 9
- Cancer therapeutics and mechanisms 3
- Pharmacological Receptor Mechanisms and Effects 3
- Ion channel regulation and function 3
Infectious Diseases 6
- Antimicrobial Resistance in Staphylococcus 6

Co-authors: James Harrison (4 shared papers)Garth T. Whiteside (10 shared papers)Katharine Walker (3 shared papers)Kenneth J. Valenzano (3 shared papers)Michelle Pearson (5 shared papers)Susan L. Gottshall (4 shared papers)James D. Pomonis (3 shared papers)Jamie Boulet (3 shared papers)
Journals: Journal of Pharmacology and Experimental Therapeutics (3 papers)Antimicrobial Agents and Chemotherapy (3 papers)Neuropharmacology (2 papers)Journal of Medicinal Chemistry (2 papers)ACS Chemical Biology (1 paper)
Partner nations: United States Canada Japan

In The Last Decade

Lilly Mark

19 papers receiving 1.4k citations

Peers

Countries citing papers authored by Lilly Mark

Since Specialization

Citations

This map shows the geographic impact of Lilly Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilly Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilly Mark more than expected).

Fields of papers citing papers by Lilly Mark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilly Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilly Mark. The network helps show where Lilly Mark may publish in the future.

Co-authors

The 25 scholars most cited alongside Lilly Mark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lilly Mark Line = papers co-authored together Lilly Mark links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology ·Kenneth J. Valenzano, Laykea Tafesse, Gary Lee, James Harrison, Jamie Boulet, Susan L. Gottshall, Lilly Mark, Michelle Pearson, Wendy Miller, Shen Shan, Leyana Rabadi, Yakov Rotshteyn, Suzanne M. Chaffer, Paul I. Turchin, David A. Elsemore, Mathew Toth, Lee Koetzner, Garth T. Whiteside	2005	233
2	N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain Journal of Pharmacology and Experimental Therapeutics ·James D. Pomonis, James Harrison, Lilly Mark, David R. Bristol, Kenneth J. Valenzano, Katharine Walker	2003	213
3	Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System Molecular Pharmacology ·Pranab K. Chanda, Ying Gao, Lilly Mark, Joan Btesh, Brian W. Strassle, Peimin Lu, Michael J. Piesla, Meiyi Zhang, Brendan Bingham, Albert J. Uveges, Dianne Kowal, David S. Garbe, Evguenia Kouranova, Robert H. Ring, Brian Bates, Menelas N. Pangalos, Jeffrey D. Kennedy, Garth T. Whiteside, Tarek A. Samad	2010	182
4	Pharmacological characterisation of a rat model of incisional pain British Journal of Pharmacology ·Garth T. Whiteside, James Harrison, Jamie Boulet, Lilly Mark, Michelle Pearson, Susan L. Gottshall, Katharine Walker	2004	137
5	Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease Osteoarthritis and Cartilage ·Brian W. Strassle, Lilly Mark, Liza Leventhal, M. Piesla, Xiaojia Li, Jeffrey D. Kennedy, S.S. Glasson, Garth T. Whiteside	2010	108
6	Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats Neuroscience ·X.-W. Dong, S. Goregoaker, Harald Engler, Xiaoping Zhou, Lilly Mark, James H. Crona, Rebecca Terry, John C. Hunter, Tony Priestley	2007	101
7	TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus Antimicrobial Agents and Chemotherapy ·Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K. Parhi, Yi Lisa Lyu, Joan Pawlak, Stephanie N. Saravolatz, Louis D. Saravolatz, Melvin P. Weinstein, Edmond J. LaVoie, Daniel S. Pilch	2015	99
8	A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833 European Journal of Pharmacology ·Garth T. Whiteside, Susan L. Gottshall, Jamie Boulet, Suzanne M. Chaffer, James Harrison, Michelle Pearson, Paul I. Turchin, Lilly Mark, Augusta E. Garrison, Kenneth J. Valenzano	2005	75
9	An FtsZ-Targeting Prodrug with Oral Antistaphylococcal Efficacy In Vivo Antimicrobial Agents and Chemotherapy ·Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K. Parhi, Edmond J. LaVoie, Daniel S. Pilch	2013	53
10	Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723 Biochemical Pharmacology ·Malvika Kaul, Lilly Mark, Yongzheng Zhang, Ajit K. Parhi, Edmond J. LaVoie, Daniel S. Pilch	2013	44
11	Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus Antimicrobial Agents and Chemotherapy ·Malvika Kaul, Lilly Mark, Ajit K. Parhi, Edmond J. LaVoie, Daniel S. Pilch	2016	41
12	Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors Neuropharmacology ·Michele Hummel, Terri Cummons, Peimin Lu, Lilly Mark, James Harrison, Jeffrey D. Kennedy, Garth T. Whiteside	2010	39
13	Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States Journal of Pharmacology and Experimental Therapeutics ·Victor I. Ilyin, James D. Pomonis, Garth T. Whiteside, James Harrison, Michelle Pearson, Lilly Mark, Paul I. Turchin, Susan L. Gottshall, Richard B. Carter, Phong Nguyen, Derk J. Hogenkamp, Shakira Olanrewaju, Elfrida R. Benjamin, Richard M. Woodward	2006	27
14	DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat Journal of Pharmacology and Experimental Therapeutics ·Garth T. Whiteside, James Harrison, Michelle Pearson, Zhengming Chen, Yakov Rotshteyn, Paul I. Turchin, James D. Pomonis, Lilly Mark, Katharine Walker, Kevin C Broglé	2004	21
15	1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors Journal of Medicinal Chemistry ·Puwen Zhang, Eugene A. Terefenko, Jenifer A. Bray, Darlene C. Deecher, Andrew Fensome, Jim Harrison, Callain Kim, Elizabeth J. Koury, Lilly Mark, Casey C. McComas, Cheryl A. Mugford, Eugene J. Trybulski, A. T. Vu, Garth T. Whiteside, Paige E. Mahaney	2009	20
16	Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus ACS Chemical Biology ·Eric J. Bryan, Edgar Ferrer-González, H.-Y. Sagong, Junso Fujita, Lilly Mark, Malvika Kaul, Edmond J. LaVoie, Hiroyoshi Matsumura, Daniel S. Pilch	2023	10
17	Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152) Journal of Medicinal Chemistry ·David J. O’Neill, Adedayo Adedoyin, Jenifer A. Bray, Darlene C. Deecher, Andrew Fensome, Joel Goldberg, Jim Harrison, Liza Leventhal, Charles W. Mann, Lilly Mark, Lisa Nogle, Nicole R. Sullivan, Taylor Spangler, Eugene A. Terefenko, Eugene J. Trybulski, Albert J. Uveges, A. T. Vu, Garth T. Whiteside, Puwen Zhang	2011	8
18	The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species Frontiers in Pharmacology ·Jessica Basso, Kuan‐Ju Chen, Yuchen Zhou, Lilly Mark, Daniel LaSala, Arielle Dorfman, Mary Atalla, Donald Chun, Veronica Viramontes, Christina C. Chang, Franziska Leifer, Patrick P. McDonald, David Cipolla	2023	7
19	Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant Staphylococcus aureus Medicinal Chemistry Research ·Malvika Kaul, Edgar Ferrer-González, Lilly Mark, Ajit K. Parhi, Edmond J. LaVoie, Daniel S. Pilch	2022	7

About Lilly Mark

Lilly Mark is a scholar working on Molecular Biology, Infectious Diseases, Pharmacology, Cellular and Molecular Neuroscience and Physiology, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (6 papers), Pain Mechanisms and Treatments (5 papers), Cancer therapeutics and mechanisms (3 papers), Neurotransmitter Receptor Influence on Behavior (3 papers), Cannabis and Cannabinoid Research (3 papers), Antibiotic Resistance in Bacteria (3 papers), Pharmacological Receptor Mechanisms and Effects (3 papers) and Ion channel regulation and function (3 papers). The work is most often cited by research in Sensory Systems (203 citations), Pharmacology (566 citations), Molecular Medicine (137 citations), Cellular and Molecular Neuroscience (451 citations) and Toxicology (77 citations). Lilly Mark has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include James Harrison, Garth T. Whiteside, Katharine Walker, Kenneth J. Valenzano, Michelle Pearson, Susan L. Gottshall, James D. Pomonis, Jamie Boulet, Malvika Kaul and Daniel S. Pilch. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Antimicrobial Agents and Chemotherapy, Neuropharmacology, Journal of Medicinal Chemistry and ACS Chemical Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact